Physician profile
Tracy Chan
NPI 1962989210
$3,158.10
in general payments reported to CMS, 2019-2025
36 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $392 · 2023: $653 · 2024: $810 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $457.95 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $451.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $293.77 | 2021-2025 | Minimed 780g |
| Dexcom, INC. | $162.02 | 2021-2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $130.57 | 2021-2025 | Tymlos |
| Sequel Med Tech, LLC | $113.86 | 2025 | Twiist |
| Insulet Corporation | $112.39 | 2023-2025 | Omnipod |
| Beta Bionics, INC. | $109.05 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.20 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $98.91 | 2022-2025 | |
| Abbott Laboratories | $81.12 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $81.10 | 2021-2024 | Farxiga, Lokelma |
| Corcept Therapeutics | $74.01 | 2023-2025 | Korlym |
| Ascensia Diabetes Care US INC. | $70.45 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $67.61 | 2023-2025 | Gvoke Hypopen, Recorlev |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $55.70 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Acella Pharmaceuticals, LLC | $51.24 | 2022-2024 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $51.07 | 2023-2025 | |
| Mannkind Corporation | $50.84 | 2022-2023 | Afrezza |
| Alvogen INC | $49.74 | 2023-2025 | Teriparatide |
| Ascendis Pharma Endocrinology INC | $48.11 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $43.28 | 2025 | Signifor Lar, Isturisa |
| Tandem Diabetes Care, INC. | $42.72 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $39.29 | 2025 | Tepezza, Evenity |
| Alexion Pharmaceuticals, INC. | $36.74 | 2023-2025 | Strensiq |
| Ibsa Pharma INC. | $36.65 | 2022-2024 | Licart, Tirosint |
| Cequr Corporation | $36.41 | 2024-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $36.31 | 2021-2025 | |
| Soleno Therapeutics, INC. | $34.58 | 2025 | Vykat Xr |
| Astellas Pharma US INC | $26.16 | 2025 | Veozah |
| Zealand Pharma US, INC. | $25.68 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $24.15 | 2024 | |
| Abbvie INC. | $20.57 | 2024 | |
| Horizon Therapeutics Plc | $19.38 | 2023 | Tepezza |
| Azurity Pharmaceuticals, INC. | $13.32 | 2023 | Horizant |
| Intuity Medical INC | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.